Showing 1,501 - 1,520 results of 28,013 for search '(( 50 ((c decrease) OR (a decrease)) ) OR ( 50 ((we decrease) OR (mean decrease)) ))', query time: 1.28s Refine Results
  1. 1501

    Synthesis and Characterization of New Organometallic Benzo[<i>b</i>]thiophene Derivatives with Potential Antitumor Properties by André P. Ferreira (2348185)

    Published 2009
    “…The benzo[<i>b</i>]thiophene derivative raloxifene is a selective estrogen receptor modulator (SERM) that has been found to decrease breast cancer risk in postmenopausal women compared to placebo. …”
  2. 1502

    Relationship between OLT and soil temperature at 50-cm (a), the depth at which charcoal was measured (b), and the active layer depth (c) measured in the field for a subset of the d... by Kristofer D Johnson (557206)

    Published 2013
    “…</strong> Relationship between OLT and soil temperature at 50-cm (a), the depth at which charcoal was measured (b), and the active layer depth (c) measured in the field for a subset of the data (<em>n</em> = 2179). …”
  3. 1503

    A long-term "memory" of HIF induction in response to chronic mild decreased oxygen after oxygen normalization-5 by Chandrashekhar D Kamat (60176)

    Published 2011
    “…<p><b>Copyright information:</b></p><p>Taken from "A long-term "memory" of HIF induction in response to chronic mild decreased oxygen after oxygen normalization"</p><p>BMC Cardiovascular Disorders 2007;7():4-4.…”
  4. 1504
  5. 1505

    2‑Aminobenzoxazole Derivatives as Potent Inhibitors of the Sphingosine-1-Phosphate Transporter Spinster Homolog 2 (Spns2) by Ariel L. Burgio (15069256)

    Published 2023
    “…To develop more potent compounds, we initiated a structure–activity relationship study that identified 2-aminobenzoxazole as a viable scaffold. …”
  6. 1506
  7. 1507

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
  8. 1508

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
  9. 1509

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
  10. 1510
  11. 1511

    IFNγ increases PRL immunoreactivity in the hair follicle, whilst TNFα decreases follicular PRL immunoreactivity. by Ewan A. Langan (405804)

    Published 2013
    “…<p>(A) PRL IR in control hair follicle outer root sheath keratinocytes (black arrows), (B) after INFγ treatment and (C) negative control. …”
  12. 1512
  13. 1513
  14. 1514
  15. 1515

    A-p50 affects tumor cell survival through inhibition of NF-κB-mediated transcriptional activation by Jing Mi (18654)

    Published 2011
    “…</p><p>© 2006 The Author(s)</p> () MTT assay of cell viability. Ad-A-p50-infected A549 cells show a significant decrease in cell viability (Ad-A-p50) compared to Ad-siNT-infected cells, = 3–5 per group, = 0.0001. () Hoechst 33342 staining of apoptotic nuclei. …”
  16. 1516

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”
  17. 1517

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”
  18. 1518
  19. 1519
  20. 1520